Comparative Bioavailability of Lenvatinib 10 mg Capsules in Healthy Subjects
Phase 1
- Conditions
- Advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery or radiation., Progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma, refractory to radioactive iodine in adults., Advanced or unresectable hepatocellular carcinoma in adults who have received no prior systemic therapy.MedDRA version: 21.1Level: LLTClassification code: 10049010Term: Carcinoma hepatocellular Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]MedDRA version: 21.1Level: LLTClassification code: 10014743Term: Endometrial carcinoma Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10007476Term: Carcinoma thyroid Class: 10029104
- Registration Number
- CTIS2022-501327-25-00
- Lead Sponsor
- Bluepharma Industria Farmaceutica S.A.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 36
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method